These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 36001024)

  • 1. Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.
    Anurag M; Jaehnig EJ; Krug K; Lei JT; Bergstrom EJ; Kim BJ; Vashist TD; Huynh AMT; Dou Y; Gou X; Huang C; Shi Z; Wen B; Korchina V; Gibbs RA; Muzny DM; Doddapaneni H; Dobrolecki LE; Rodriguez H; Robles AI; Hiltke T; Lewis MT; Nangia JR; Nemati Shafaee M; Li S; Hagemann IS; Hoog J; Lim B; Osborne CK; Mani DR; Gillette MA; Zhang B; Echeverria GV; Miles G; Rimawi MF; Carr SA; Ademuyiwa FO; Satpathy S; Ellis MJ
    Cancer Discov; 2022 Nov; 12(11):2586-2605. PubMed ID: 36001024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
    Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
    Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
    Filho OM; Stover DG; Asad S; Ansell PJ; Watson M; Loibl S; Geyer CE; Bae J; Collier K; Cherian M; O'Shaughnessy J; Untch M; Rugo HS; Huober JB; Golshan M; Sikov WM; von Minckwitz G; Rastogi P; Maag D; Wolmark N; Denkert C; Symmans WF
    JAMA Oncol; 2021 Apr; 7(4):603-608. PubMed ID: 33599688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins.
    Wang J; Saltzman AB; Jaehnig EJ; Lei JT; Malovannaya A; Holt MV; Young MN; Rimawi MF; Ademuyiwa FO; Anurag M; Kim BJ; Ellis MJ
    Cancer Res Commun; 2023 Aug; 3(8):1551-1563. PubMed ID: 37587913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosome 12p Amplification in Triple-Negative/
    Gómez-Miragaya J; Díaz-Navarro A; Tonda R; Beltran S; Palomero L; Palafox M; Dobrolecki LE; Huang C; Vasaikar S; Zhang B; Wulf GM; Collado-Sole A; Trinidad EM; Muñoz P; Paré L; Prat A; Bruna A; Caldas C; Arribas J; Soler-Monso MT; Petit A; Balmaña J; Cruz C; Serra V; Pujana MA; Lewis MT; Puente XS; González-Suárez E
    Cancer Res; 2019 Aug; 79(16):4258-4270. PubMed ID: 31213465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial.
    Sipos O; Tovey H; Quist J; Haider S; Nowinski S; Gazinska P; Kernaghan S; Toms C; Maguire S; Orr N; Linn SC; Owen J; Gillett C; Pinder SE; Bliss JM; Tutt A; Cheang MCU; Grigoriadis A
    Ann Oncol; 2021 Jan; 32(1):58-65. PubMed ID: 33098992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
    Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
    Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.
    Echavarria I; López-Tarruella S; Picornell A; García-Saenz JÁ; Jerez Y; Hoadley K; Gómez HL; Moreno F; Monte-Millan MD; Márquez-Rodas I; Alvarez E; Ramos-Medina R; Gayarre J; Massarrah T; Ocaña I; Cebollero M; Fuentes H; Barnadas A; Ballesteros AI; Bohn U; Perou CM; Martin M
    Clin Cancer Res; 2018 Apr; 24(8):1845-1852. PubMed ID: 29378733
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
    Ademuyiwa FO; Chen I; Luo J; Rimawi MF; Hagemann IS; Fisk B; Jeffers G; Skidmore ZL; Basu A; Richters M; Ma CX; Weilbaecher K; Davis J; Suresh R; Peterson LL; Bose R; Bagegni N; Rigden CE; Frith A; Rearden TP; Hernandez-Aya LF; Roshal A; Clifton K; Opyrchal M; Akintola-Ogunremi O; Lee BH; Ferrando-Martinez S; Church SE; Anurag M; Ellis MJ; Gao F; Gillanders W; Griffith OL; Griffith M
    Breast Cancer Res Treat; 2021 Aug; 189(1):187-202. PubMed ID: 34173924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
    Telli ML; Jensen KC; Vinayak S; Kurian AW; Lipson JA; Flaherty PJ; Timms K; Abkevich V; Schackmann EA; Wapnir IL; Carlson RW; Chang PJ; Sparano JA; Head B; Goldstein LJ; Haley B; Dakhil SR; Reid JE; Hartman AR; Manola J; Ford JM
    J Clin Oncol; 2015 Jun; 33(17):1895-901. PubMed ID: 25847929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
    Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
    Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
    Ueno T; Kitano S; Masuda N; Ikarashi D; Yamashita M; Chiba T; Kadoya T; Bando H; Yamanaka T; Ohtani S; Nagai S; Nakayama T; Takahashi M; Saji S; Aogi K; Velaga R; Kawaguchi K; Morita S; Haga H; Ohno S; Toi M
    BMC Med; 2022 Apr; 20(1):136. PubMed ID: 35462552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
    Zhang L; Wu ZY; Li J; Lin Y; Liu Z; Cao Y; Zhang G; Gao HF; Yang M; Yang CQ; Zhu T; Cheng MY; Ji F; Li J; Wang K
    Int J Cancer; 2022 Feb; 150(4):654-662. PubMed ID: 34591977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
    Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
    Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.
    Vici P; Di Benedetto A; Ercolani C; Pizzuti L; Di Lauro L; Sergi D; Sperati F; Terrenato I; Dattilo R; Botti C; Fabi A; Ramieri MT; Mentuccia L; Marinelli C; Iezzi L; Gamucci T; Natoli C; Vitale I; Barba M; Mottolese M; De Maria R; Maugeri-Saccà M
    Oncotarget; 2015 Dec; 6(40):42773-80. PubMed ID: 26544894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Platinums in Triple-Negative Breast Cancer.
    Lynce F; Nunes R
    Curr Oncol Rep; 2021 Mar; 23(5):50. PubMed ID: 33754211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
    Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
    Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response.
    Kern P; Kalisch A; Kolberg HC; Kimmig R; Otterbach F; von Minckwitz G; Sikov WM; Pott D; Kurbacher C
    Chemotherapy; 2013; 59(5):387-94. PubMed ID: 24852315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.